ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D
08:09 EDT 17 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
ADC Therapeutics (ADCT), the drug development company targeting cancers
with antibody-drug conjugate (ADC) “warhead” therapies, today announced
the appointment of former Genmab Vice President Dr Patrick van Berkel as
Senior ...
Other Sources for this Article
College Hill Life Sciences
Sue Charles/Gemma Howe/Dr Rebecca Caygill
+44
(0)20 7866 7866
or
Rebecca Skye Dietrich
+1 857 241 0795
celtic@collegehill.com
or
At
Celtic Therapeutics Management (on behalf of ADC Therapeutics)
Investor
Relations
Ms. Kathy Armstrong
+1 (212) 616 4042
kathy.armstrong@celtictherapeutics.com
More From BioPortfolio on "ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
